[{"id":"77eb3cd1-2540-4b18-b06d-2e8b7aee2b46","acronym":"NCI-2018-00872","url":"https://clinicaltrials.gov/study/NCT03452930","created_at":"2021-07-05T17:12:08.426Z","updated_at":"2024-07-02T16:35:03.679Z","phase":"Phase 1","brief_title":"Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma","source_id_and_acronym":"NCT03452930 - NCI-2018-00872","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinostamustine (EDO-S101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-15"},{"id":"cc080d0a-7db6-4ca7-8542-67f634287ac5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432375","created_at":"2022-06-27T14:54:10.811Z","updated_at":"2024-07-02T16:35:22.487Z","phase":"Phase 1","brief_title":"Study of Tinostamustine for Adjuvant Treatment of Glioblastoma","source_id_and_acronym":"NCT05432375","lead_sponsor":"Mundipharma Research Limited","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • tinostamustine (EDO-S101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-01-23"},{"id":"99b4c267-9f38-4f12-98ce-bb6c9d071727","acronym":"","url":"https://clinicaltrials.gov/study/NCT04279938","created_at":"2021-01-18T20:46:54.920Z","updated_at":"2025-02-25T16:10:02.131Z","phase":"Phase 1","brief_title":"A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL","source_id_and_acronym":"NCT04279938","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Rituxan (rituximab) • tinostamustine (EDO-S101)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2020-02-21"}]